WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H526471
CAS#: 88107-10-2
Description: Tomelukast, also known as LY171883, is a leukotriene inhibitor. Tomelukast showed protective effects in traumatic shock. LY-171883 stimulates the activity of BK(Ca) channels in a manner unlikely to be linked to its blockade of leukotriene receptors or stimulation of peroxisome proliferator-activated receptors. The stimulatory effects on these channels may, at least in part, contribute to the underlying cellular mechanisms by which LY-171883 affects neuronal or neuroendocrine function.
Hodoodo Cat#: H526471
Name: Tomelukast
CAS#: 88107-10-2
Chemical Formula: C16H22N4O3
Exact Mass: 318.17
Molecular Weight: 318.377
Elemental Analysis: C, 60.36; H, 6.97; N, 17.60; O, 15.08
Synonym: Tomelukast; LY171883; LY-171883; LY 171883.
IUPAC/Chemical Name: Ethanone, 1-(2-hydroxy-3-propyl-4-(4-(1H-tetrazol-5-yl)butoxy)phenyl)-
InChi Key: MWYHLEQJTQJHSS-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H22N4O3/c1-3-6-13-14(9-8-12(11(2)21)16(13)22)23-10-5-4-7-15-17-19-20-18-15/h8-9,22H,3-7,10H2,1-2H3,(H,17,18,19,20)
SMILES Code: CC(C1=CC=C(OCCCCC2=NN=NN2)C(CCC)=C1O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 318.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Moreno JJ. Eicosanoid receptors: Targets for the treatment of disrupted intestinal epithelial homeostasis. Eur J Pharmacol. 2016 Dec 7;796:7-19. doi: 10.1016/j.ejphar.2016.12.004. [Epub ahead of print] Review. PubMed PMID: 27940058.
2: Reques FG, Rodriguez JL. Tolerability of leukotriene modifiers in asthma: a review of clinical experience. BioDrugs. 1999 Jun;11(6):385-94. PubMed PMID: 18031150.
3: Shahbazian A, Heinemann A, Peskar BA, Holzer P. Differential peristaltic motor effects of prostanoid (DP, EP, IP, TP) and leukotriene receptor agonists in the guinea-pig isolated small intestine. Br J Pharmacol. 2002 Dec;137(7):1047-54. PubMed PMID: 12429577; PubMed Central PMCID: PMC1573581.
